The Food and Drug Administration approved a combination of durvalumab and enfortumab vedotin for adults with muscle-invasive bladder cancer who cannot receive cisplatin chemotherapy or choose not to undergo that treatment. The approval was issued Friday, six weeks before the agency’s target decision date.
The treatment pairs Imfinzi, the brand name for durvalumab, with Padcev, the brand name for enfortumab vedotin. In the VOLGA trial, patients received three cycles of the combination before surgery. The trial found a 42% reduction in the risk of death compared with standard care, according to the data cited in the approval announcement.
Why cisplatin eligibility matters
Muscle-invasive bladder cancer has grown into the bladder’s deeper muscle layer and is commonly treated with surgery to remove the bladder, a procedure known as radical cystectomy. Cisplatin-based chemotherapy is often given before surgery, but the drug can damage the kidneys. Reduced kidney function is therefore a frequent reason that patients cannot receive it.
As many as 50% of the roughly 15,000 people treated for muscle-invasive bladder cancer in the United States in 2026 may be unable to receive cisplatin, according to the priority review announcement. For patients who do not receive chemotherapy before surgery, radical cystectomy may proceed without that preliminary treatment. About half of patients undergoing cystectomy experience a recurrence, the announcement said.
- The VOLGA trial evaluated three cycles of durvalumab and enfortumab vedotin before surgery.
- The combination was associated with a 42% lower risk of death than standard care.
- Grade 3 or higher adverse events occurred in 71.1% of patients receiving the regimen.
Benefits and safety concerns
Durvalumab is a PD-L1 blocker, while enfortumab vedotin is an antibody-drug conjugate directed at Nectin-4, a protein found in high amounts on bladder cancer cells. The antibody carries a cell-killing compound called monomethyl auristatin E. After the drug binds to a cancer cell and enters it, the compound interferes with cell division.
The treatment also carries important safety risks. Grade 3 or higher adverse events affected 71.1% of patients in the VOLGA trial, indicating severe or medically significant events under the trial’s grading system. Padcev has a boxed warning for serious and potentially fatal skin reactions. Other risks associated with the regimen must be weighed against its benefit in the population covered by the approval.
The FDA’s decision applies to adults with muscle-invasive bladder cancer who are ineligible for cisplatin or decline it. It adds a preoperative treatment option for a group of patients for whom kidney-related limitations can rule out the chemotherapy regimen commonly used before bladder-removal surgery. The approval is based on the VOLGA results, including the survival finding and the adverse-event data reported in the trial.